Holen Sie sich die Stockscreener-App
3.1101
2.50%
-0.0799
Schlusskurs vom Vortag:
$3.19
Offen:
$3.15
24-Stunden-Volumen:
1,261
Relative Volume:
0.10
Marktkapitalisierung:
$22.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-3.8558
EPS:
-0.8066
Netto-Cashflow:
-
1W Leistung:
-4.89%
1M Leistung:
+12.68%
6M Leistung:
+1.97%
1J Leistung:
+29.05%
1-Tages-Spanne:
$3.11
$3.15
1-Wochen-Bereich:
$3.03
$3.41
52-Wochen-Spanne:
$2.00
$3.89
Neuraxis Inc Stock (NRXS) Company Profile
Firmenname
Neuraxis Inc
Sektor
Branche
Telefon
(812) 689-0791
Adresse
11550 North Meridian Street, Suite 325, Carmel
Vergleichen Sie NRXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NRXS | 3.1101 | 22.96M | 0 | 0 | 0 | -0.8066 |
| VRTX | 447.31 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.17 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.86 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.13 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS) - Defense World
NeurAxis, Inc. (NASDAQ:NRXS) Q3 2024 Earnings Call Transcript - MSN
Neuraxis secures $5 million in preferred stock sale By Investing.com - Investing.com Canada
Neuronetics Grants Inducement Awards to New Employees - MSN
NeurAxis Stock Surges After Strong Q3 Earnings And Expanded Coverage - Barchart
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage - Yahoo Finance
NeurAxis reports 40% increase in revenues in Q3 2024 - Medical Buyer
NeurAxis Reports Strong Revenue Growth in Q3 2024 - TipRanks
Neuraxis Inc. (NRXS) Quarterly 10-Q Report - Quartzy
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues - GlobeNewswire
NeurAxis Q3 Revenue Surges 40%, Expands Coverage to 35M Lives Amid FDA Milestone | NRXS Stock News - StockTitan
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market - Building Indiana
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 - GlobeNewswire
NeurAxis (NRXS) Sets Q3 2024 Earnings Call for November 12 | Neuromodulation Leader | NRXS Stock News - StockTitan
IRIDEX (NASDAQ:IRIX) versus NeurAxis (NASDAQ:NRXS) Financial Survey - Defense World
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024 - The Manila Times
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation - GlobeNewswire
Neuraxis adjusts equity agreement, secures additional funding - Investing.com India
Creatd (NASDAQ:VOCL) Stock Price Down 4.4% – Should You Sell? - Defense World
Technip Energies (OTCMKTS:THNPY) Trading Up 0.7% – Here’s What Happened - Defense World
Vestas Wind Systems A/S (OTCMKTS:VWSYF) Shares Up 1.2% – Here’s What Happened - Defense World
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation - Yahoo Finance
The Zacks Analyst Blog Highlights Costco Wholesale, Alibaba, GE Aerospace, Applied Energetics and NeurAxis - Yahoo Finance
Top Analyst Reports for Costco Wholesale, Alibaba & GE Aerospace - Yahoo Finance
NeurAxis (NASDAQ:NRXS) Trading Up 6% - Defense World
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewswire
Neuraxis issues shares in equity financing By Investing.com - Investing.com Australia
Neuraxis issues shares in equity financing - Investing.com
Fishers startup prepares to go public - Greenfield Daily Reporter
NeurAxis (NASDAQ:NRXS) Stock Price Down 2.2% - Defense World
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024 - GlobeNewswire
Vagus Nerve Stimulators Market Projected to Witness Huge Growth - openPR
Neuraxis shareholders approve key proposals at annual meeting - Investing.com
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024 - GlobeNewswire
NeurAxis revenue down 5.3% to USD 611.5K in Q2 2024 - Medical Buyer
NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript - Seeking Alpha
Contrasting Sonova (OTCMKTS:SONVY) & NeurAxis (NASDAQ:NRXS) - Defense World
NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024 - MSN
NeurAxis Reports Second Quarter 2024 Financial Results - GlobeNewswire
NeurAxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Vagus Nerve Stimulators Market Is Booming Worldwide 2024-2031 | - openPR
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024 - GlobeNewswire
Finanzdaten der Neuraxis Inc-Aktie (NRXS)
Es liegen keine Finanzdaten für Neuraxis Inc (NRXS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
Kapitalisierung:
|
Volumen (24h):